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Epidemiology and incidence
Nasopharyngeal carcinoma (NPC) has a remarkably distinctive
ethnic and geographic distribution. In the year 2000, a total of
64,798 new cases were registered worldwide, and more than
80% of those were reported from China, Southeast Asia, and
some Asian countries (Ferlay et al., 2001). NPC is a rare malig-
nant disease, with an incidence well under 1 per 100,000 per-
sons per year in Caucasians from North America and other
Western countries. In contrast, the highest incidence is found
among Southern Chinese (?25–30 per 100,000 persons per
year), especially those of Cantonese origin. Southern Chinese
immigrants also have a higher risk of NPC as compared to the
local Western population. Early-age onset of NPC is observed
in high-risk populations. Independent of race/ethnicity, men are
2- to 3-fold more frequently affected than women (Yu and Yuan,
2002). The dramatic difference in the incidence among popula-
tions and geographic areas suggests a strong association of
NPC with genetic and environmental factors. An unusually
early-age onset in the high-risk populations implies that early
events in life may be important. There are recent changes in the
epidemiology as shown by decreasing incidences of NPC
(?30%) in Hong Kong over the past 20 years (Lee et al., 2003),
which may be related to changes in environmental factors, as
discussed later.
A distinctive type of head and neck cancer
NPC is a distinctive type of head and neck cancer. The World
Health Organization (WHO) classification distinguishes three
histopathological types of NPC based on the degree of differen-
tiation. Type I is keratinizing squamous cell carcinoma (SCC),
similar to other head and neck cancer. Type II is nonkeratinizing
carcinoma, and Type III is undifferentiated carcinoma
(Shanmugaratnam and Sobin, 1991). The undifferentiated car-
cinoma has a typical morphology with a prominent lymphoplas-
macytic infiltrate, and is also referred as “lymphoepithelioma.”
Different prevalent histologic types of NPC are found in endem-
ic and nonendemic regions. In endemic areas such as Southern
China, WHO Type III accounts for more than 97%, while kera-
tinizing SCC is more common in the Western countries (?75%)
(Marks et al., 1998). Aside from differences in histological fea-
tures, latent Epstein-Barr virus (EBV) infection is uniquely pre-
sent in almost all, if not all, NPC from endemic regions, but
absent in WHO Type I NPC from nonendemic regions (Figure 1)
(Raab-Traub, 2002). Alternative pathogenic processes of EBV-
negative NPC, especially WHO Type I from Western popula-
tions, may be involved.
Etiologies
The ethnic clustering of NPC in Southern Chinese strongly
suggests the involvement of genetic susceptibility and environ-
mental factors in its development. Three major etiological fac-
tors, including genetic, environmental, and viral factors, are
defined here.
Genetic factors
Early linkage analysis on Chinese sib pair studies of NPC sug-
gested the association of susceptibility HLA haplotypes with
NPC development. The investigators hypothesized that some of
the HLA antigens have reduced efficiency in activating host
immune response to EBV infection, which plays a critical role in
the pathogenesis of NPC. Most studies conducted among
Chinese showed that individuals with HLA-A2 are at increased
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Figure 1. EBV latent infection in nasopharyngeal carcinoma
A and B: Typical nasopharyngeal undifferentiated carcinoma (WHO type
III). A: The carcinoma cells exhibit prominent nucleoli and arrange in syncy-
tial clusters. Dense infiltration of lymphocytes and plasma cells is evident
(hematoxylin and eosin stain [H&E], 400×). B: In situ hybridization (ISH) for
EBV RNA (EBER) reveals distinct nuclear positivity, indicative of latent infec-
tion in carcinoma cells (400×). 
C and D: Squamous cell carcinoma (SCC, WHO type I) from endemic
region. C: SCC with intercellular bridges and keratinization is seen (H&E,
400×). D: ISH-EBV is positive (400×). 
E and F: SCC (WHO type I) from nonendemic region. E: SCC with intercellu-
lar bridges, keratinization, and keratin pearl are noted (H&E, 400×). F: ISH-
EBV is negative (400×).
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risk. A recent high-resolution genotyping study has detected a
consistent association between NPC and the prevalent Chinese
A2 subtype (HLA-A*0207), but not the prevalent Caucasian sub-
type (HLA-A*0201) (Hildesheim et al., 2002). Supported by
affected sib pair haplotype sharing analysis and association
study on HLA regions, a NPC susceptible gene/locus closely
linked to the MHC region but distinct from the HLA genes was
proposed (Lu et al., 1990). However, recent linkage analysis of
Chinese NPC pedigrees using highly polymorphic microsatellite
markers further identified two susceptibility loci on chromo-
somes 4p15.1-q12 and 3p21, respectively, but not on MHC
region, from the Guangdong and Hunan provinces in China
(Feng et al., 2002a; Xiong et al., 2004). Polymorphisms of genes
for carcinogen metabolism (CYP2E1), detoxification (GSTM1),
and DNA repair (XRCC1 and hOGG1) were also reported to be
associated with increased risk of NPC (Hildesheim et al., 1997;
Nazar-Stewart et al., 1999; Cho et al., 2003).
Environmental factors
The traditional foods of Southern Chinese, such as Cantonese-
style salted fish and other preserved foods containing volatile
nitrosamines, are an important carcinogenic factor for NPC.The
childhood consumption of salted fish has been shown to be
related to an increased risk of NPC in Southern Chinese (Yu
and Yuan, 2002). In animal studies, nasal and nasopharyngeal
tumors could be induced in rats by feeding them Chinese salted
fish (Huang et al., 1978). These traditional diets may act as
chemical carcinogens that induce genetic damage in nasopha-
ryngeal epithelial cells.The decreasing trend in NPC incidences
(?30%) in Hong Kong may be attributed to the change of tradi-
tional lifestyle, particularly the avoidance of feeding young chil-
dren salted fish. The use of Chinese medicinal herbs has been
suggested to increase the risk for NPC by reactivating EBV
infection in the host. The association of NPC with other nondi-
etary factors such as cigarette smoking or formaldehyde expo-
sure is either weak or controversial.
Epstein-Barr virus (EBV)
In contrast to other head and neck cancer and epithelial malig-
nancy in general, a unique feature of NPC is its strong associa-
tion with EBV. Higher EBV antibody titers, especially of IgA
class, are observed in most NPC patients. Latent EBV infection
is identified in cancer cells of virtually all cases of NPC in
endemic regions. The clonal EBV genome is consistently
detected in invasive carcinomas and high-grade dysplastic
lesions (Raab-Traub and Flynn, 1986; Raab-Traub, 2002). Such
observations imply that viral latent infection may have taken
place before the expansion of the malignant cell clone. A current
hypothesis proposes that EBV plays a critical role in transform-
ing nasopharyngeal epithelial cells into invasive cancer.
Clinical features, staging, and treatment
The majority of NPCs arise in the lateral walls, especially from
the fossa of Rosenmuller and Eustachian tube cushions. Neck
mass, blood-tinged sputum, nasal obstruction and increasing
nasal discharge, aural symptoms such as tinnitus, stuffiness,
and hearing loss, frequent headache, and neurological symp-
toms are common clinical presentations. Since the nasophar-
ynx has an abundant supply of regional lymphatic vessels,
metastasis is frequently found, and cervical lymphadenopathy
is often the only clinical manifestation of NPC patients.
By incorporating all the major prognostically significant
tumor parameters (nasopharynx [T], regional lymph node [N],
and distant metastasis [M])—parameters previously used for
forming several staging systems—a new UICC/AJCC staging
classification was introduced in 1997 (Lee et al., 1999).The new
system assigns patients to more uniform-size stage groupings
and correlates better with prognosis than previous staging sys-
tems; e.g., Ho 1978 system and 1992 UICC/AJCC system.
Moreover, in addition to computed tomography (CT) scans,
magnetic resonance imaging (MRI) has been utilized to better
delineate the skull base and brain involvement, a factor of con-
siderable treatment and prognostic significance.The role of new
imaging approaches, including positron-emission tomography
(PET), is still being investigated.
Since NPC is highly radiosensitive, radiotherapy (RT) has
always been the main treatment of choice for this cancer. With
conventional practice and two-dimensional planning tech-
niques, the local control rates were in the order of 80%, taking
all T stages together. Intensity-modulated radiotherapy (IMRT)
provides superior local control and better delineation of tumor
target volume and spares the adjacent vital organs (Teo and
Chan, 2002). With excellent local control, IMRT has replaced
conventional RT as standard practice in centers where the tech-
nique is available. Although overall survival after RT for early
staging is encouraging, there are significant rates of local failure
and distant metastases subsequent to RT in the advanced
stage disease. Attempts have been made to improve treatment
results by integrating RT with some form of chemotherapy. The
current standard of care is RT for early disease and concurrent
chemotherapy-RT in locally advanced disease (Teo and Chan,
2002). Preliminary results on the use of neoadjuvant
chemotherapy followed by concurrent chemoradiation are
highly encouraging. The additional benefit of neoadjuvant
chemotherapy in combination with concurrent chemotherapy-
RT is being investigated in prospective randomized studies.
Molecular alterations and pathogenesis
Genetic and epigenetic events
The genetic, environmental, and viral causative factors, either
acting alone or in combination, would lead to multiple genetic
and epigenetic alterations. By the comprehensive genome-wide
studies, multiple genetic defects have been identified in this
EBV-associated cancer. Consistently high frequencies of genet-
ic losses are observed on chromosomes 3p, 9, 11q, 13q, 14q,
and 16q, while recurrent chromosomal gains were identified on
chromosome 12 (Hui et al., 1999; Lo et al., 2000a). In particular,
the inactivation of tumor suppressor genes on 3p, 9p, and 14q
appears to be a critical event, since deletion of these chromoso-
mal regions was detected in almost all microdissected NPC
samples (Lo et al., 2000a). Genes located on chromosomes
9p21 (p14, p16) and 3p21.3 (RASSF1A) were found to be
defective due to deletion or promoter hypermethylation (Lo et
al., 1996, 2001; Kwong et al., 2002). The tumor suppressor
properties of p16 and RASSF1A have also been demonstrated
in NPC cells (Wang et al., 1999; Chow et al., 2004).
Frequent promoter hypermethylation of cancer genes is an
important feature of NPC. Apart from the common tumor sup-
pressors, such as RASSF1A and p16, genome-wide aberrant
methylation disrupts multiple cellular functions through the inac-
tivation of retinoid signaling pathway (e.g., RARB2), endothelin-
1 pathway (e.g., EDNRB), cell adhesion (e.g., E-cadherin,
TSLC-1), and other novel pathways (e.g., HIN-1) (Lo and
Huang, 2002; Kwong et al., 2002; Hui et al., 2003). Such wide-
spread hypermethylation in the NPC genome may imply a
“methylator” phenotype of this EBV-associated cancer.
Induction of epigenetic alterations of cellular genes was pro-
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posed as one of the mechanisms for enhancing the transforma-
tion of nasopharyngeal epithelial cells by EBV infection (Lo and
Huang, 2002).
Alterations of cellular mechanisms
In NPC, multiple genetic abnormalities result in the disruption of
various cellular mechanisms (Table 1). Alteration of cell cycle
regulation by disrupting Rb and p53 pathways appears to be a
critical event for NPC. The p16 gene, an important cell cycle
regulator for G1 restriction checkpoint, is inactivated in
62%–86% of primary tumors. Loss of p16 may result in constitu-
tional Rb phosphorylation and uncontrolled proliferation of NPC
cells (Lo et al., 1996). On the other hand, in spite of the absence
of p53 mutation, functional disruption of p53 pathway through
inactivation of p14 and overexpression of truncated ∆N-isoform
of p63 was common in this cancer (Kwong et al., 2002; Crook et
al., 2000). Since p14 binds MDM2 and inhibits the ubiquitination
of p53 protein, the inactivation of p14 may facilitate p53 degra-
dation in NPC cells. Alternatively, ∆N-p63, as a p53 homolog,
can block p53-mediated transactivation through its dominant
negative function. Transcriptional silencing of the newly identi-
fied tumor suppressor, RASSF1A, is found in the majority of
NPCs, although it is rarely involved in other head and neck can-
cers. Novel tumor suppressor function has been proven in NPC
cells both in vitro and in vivo (Chow et al., 2004). Although
RASSF1A-associated pathways in NPC are still unclear, our
recent microarray study suggests that the gene may play roles
in G protein signaling and TGF-β pathway in this particular
cancer.
Aside from cell cycle regulation, multiple abnormalities
associated with apoptosis and growth signals are found.
Consistent upregulation of Bcl2 in precancerous lesions and
invasive tumors suggests that alterations in the apoptotic
response are early events in the transformation pathway (Lu et
al., 1993). Overexpression of metallothionein (MT) and Id1, and
loss of DAP-kinase may also contribute to the inhibition of apop-
tosis (Jayasurya et al. 2000; Kwong et al., 2002; Wang et al.
2002). Specific activation of NF-kB p50 homodimer and overex-
pression of Bcl3 may increase the proliferative capacity of NPC
cells through transcriptional upregulation of target genes, such
as EGFR (Thornburg et al., 2003). Furthermore, the c-Met tyro-
sine kinase, metalloproteinases (MMPs), and the hypoxia pro-
teins such as HIF-1 α and CA IX were found to be
overexpressed in the majority of NPCs
and associated with the progression or
metastasis of this cancer (Qian et al.,
2002; Hui et al., 2002; Lu et al., 2003).
The elevation of EGFR, MET, and hypox-
ia protein expression provides attractive
targets for the development of novel
chemotherapeutic strategies.
Roles of EBV latent infection
As a cancer-associated herpesvirus,
EBV infects over 90% of the world’s pop-
ulation. After primary infection at early
age, persistent EBV latent infection is found in some resting B
cells, but not in the nasopharyngeal epithelia of healthy individ-
uals. The mechanisms for EBV entry into epithelial cells and
maintenance of latency remain poorly understood. Recent evi-
dence demonstrated the association of distinct lytic promoter
sequence variation with NPC in Southern Chinese and suggest-
ed the participation of a lytic-latent switch of EBV in NPC car-
cinogenesis (Tong et al., 2003). In NPC cells, the virus is in the
form of episome and not integrated into the host genome. EBV
adopts a specific form of latent infection, latency II, in NPC cells.
Only limited viral genes, including EBERs, EBNA1, LMP1,
LMP2, BARF1, and several BamHI A transcripts are expressed
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Figure 2. Multistep carcinogenesis of
nasopharyngeal carcinoma
Hematoxylin and eosin staining and EBER in situ
hybridization of the dysplastic lesions and inva-
sive carcinoma are shown in the upper and
lower panels, respectively.
Table 1. Major gene alterations in nasopharyngeal carcinoma
Chromosome
Gene Mechanisms Frequencies regions
Cell cycle 
regulation 
p16/CDNK2A Homozygous deletion 62%86% 9p21
and hypermethylation
p14/ARF Homozygous deletion 54% 9p21
and hypermethylation
∆N-p63 Overexpression 100% 3q27-28
Apoptosis 
Bcl 2 Overexpression 80% 18q21.3
DAP-kinase Hypermethylation 76% 9q34.1
Signal 
transduction 
Bcl 3 Overexpression 60% 19q13.1-13.2
EGFR Overexpression 85% 7p12
Cell adhesion
E-cadherin Hypermethylation 52% 16q22.1
TSLC 1 Hypermethylation 34.2% 11q23.2
Other novel 
pathways
RASSF1A Hypermethylation 67%83% 3p21.3
and mutation
RARB2 Hypermethylation 80% 3p24
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(Raab-Traub, 2002). LMP1 and BARF1 have profound effects
on cellular gene expression and may contribute to EBV-mediat-
ed tumorigenesis. LMP1 is considered to be a viral oncogene,
since it shows transforming activity in various cell types in vitro.
Expression of LMP1 in immortalized nasopharyngeal epithelial
cells induces an array of genes involved in growth stimulation,
enhanced survival, and increased invasive potentials (Lo et al.,
2004). BARF1 is able to immortalize primate epithelial cells and
enhance growth rate of the transfected cells (Wei et al., 1997).
Nevertheless, in vitro EBV infection of nasopharyngeal epithe-
lial cells did not result in apparent growth stimulation or changes
in cell cycle and apoptosis (our unpublished data). In contrast,
enhancement in invasiveness and migration of the infected cells
was observed. It appears that EBV infection may promote
tumorigenicity of NPC cells by enhancing its invading activity.
Moreover, EBV-infected normal nasopharyngeal epithelial cells
are not able to form tumors in nude mice. Thus, in addition to
EBV, other somatic genetic changes or epigenetic events
appear to be necessary for the malignant transformation of
nasopharyngeal epithelial cells.
Multistep carcinogenesis
Preinvasive lesions in the nasopharynx are rarely encountered
in clinical settings; however, such preinvasive dysplastic lesions
are considered to precede the development of invasive NPC.
High frequencies of chromosome 3p and 9p deletions are found
in both low-grade and high-grade dysplastic lesions (Chan et
al., 2000, 2002a). However, EBV infection is consistently
observed in NPC and high-grade but not low-grade dysplastic
lesions. These findings suggest that the involvement of those
specific genetic changes precedes EBV infection during the ini-
tiation of NPC development. Furthermore, chromosome 3p and
9p deletions were also commonly observed in histologically nor-
mal nasopharynx epithelia from Southern Chinese, the high-
risk population. The presence of multiple lesions with clonal
allelic deletions in nasopharyngeal mucosa provides the evi-
dence for field cancerization during the initiation of this cancer.
Disruption of the NPC-associated tumor suppressor genes on
these critical regions, such as p16 and p14 on 9p21 and
RASSF1A on 3p21.3, may lead to immortalization and clonal
proliferation of multiple genetic lesions in the nasopharyngeal
mucosa during the initiation stage. On the other hand, early
genetic changes may predispose the epithelial cells to EBV
infection or persistent maintenance of latent cycle. Expression
of latent genes in the EBV-infected cells may enhance its trans-
formation capacities, and subsequently, clonal expansion may
result in the rapid progression to invasive carcinoma (Figure 2).
Recent advances in cancer detection
NPC shows a remarkably high cure rate for early-stage disease,
and early detection is critical to improve the overall prognosis of
these patients. However, the clinical presenting features of NPC
are often nonspecific, and examination of nasopharynx requires
expertise and renders early detection difficult.
Since EBV shows a strong link to NPC, and a wide spec-
trum of EBV antigens are consistently elevated in the sera of
NPC patients, EBV-specific antibody-based assays have been
used for at least two decades as diagnostic markers in high-risk
regions. EBV-related antibodies in NPC, such as IgA antibodies
against viral capsid antigen (VCA), early antigen (EA) and
nuclear antigen (EBNA), and DNase assay have been found to
be useful markers in clinical practice and correlate well with dis-
ease status. A mass screening study in Southern China showed
that the interval between raised IgA anti-VCA detection and
clinical onset of Stage I cancer ranges between 8 and 30
months (Zeng, 1985). A recent study of 9,699 Taiwanese with
16 years of followup has also revealed that seropositivity for IgA
anti-EBV VCA and neutralizing antibodies against EBV DNase
are predictive of NPC (Chien et al., 2001).The raised titers iden-
tify high-risk individuals for further diagnostic evaluation and
may improve the chance of early cancer detection.
The serological tests have limited roles in monitoring dis-
ease progress and detecting recurrent diseases. A novel sensi-
tive molecular test for NPC, based on detecting circulating EBV
DNA in blood plasma, has recently been developed (Lo et al.,
1999). Using real-time quantitative PCR, cell-free EBV DNA
was found in the plasma of 96% of NPC. Pretreatment EBV
DNA levels in plasma or serum are correlated with tumor stage
and overall survival. Moreover, posttreatment plasma EBV DNA
levels can accurately reflect the posttreatment residual tumor
load and predict recurrence and prognosis (Lo et al., 2000b;
Chan et al., 2002b). Plasma EBV DNA becomes one of the
most promising diagnostic and prognostic molecular markers
for routine clinical use in NPC patients.
Tumor-specific methylation has also been detected in the
serum of NPC patients, but with less sensitivity (Wong et al.,
2004). The detection of multiple gene methylation and EBV
copy number from brushing samples collected directly from the
nasopharynx was shown to be a noninvasive and sensitive
diagnostic test for NPC (Tong et al., 2002). Such an approach
allows us to directly investigate the disease progression in the
nasopharynx. By combining with plasma EBV DNA, the sensi-
tivity may further improve to near 100%.
Molecular targets and gene therapy
EBV-targeting therapy
The presence of EBV in tumor cells provides a potential thera-
peutic target specific for NPC. EBV-targeting therapeutic strate-
gies have been developed for the control of advanced stage
NPC. By either pharmacologic agents or adenovirus expressing
EBV-early immediate lytic proteins, induction of lytic cycle pro-
tein expression in EBV-positive NPC cell lines has been demon-
strated (Feng et al., 2002b, 2002c). The results support further
clinical trials by the induction of lytic infection and antiviral
agents.
Cellular immunotherapy with EBV-specific cytotoxic T lym-
phocytes (CTLs) represents another approach for EBV-target-
ing therapy. Despite limited EBV protein expression in NPC
cells, LMP-2 and EBNA-1 from NPC cells were demonstrated to
be the targets for CD8+ and CD4+ T cells, respectively.
Intratumoral functional CTLs and LMP2-specific CTL responses
can be detected in the untreated NPC patients. The intact anti-
gen-processing pathways in NPC cell lines also support the use
of therapeutic vaccination (Lee et al., 2000).To enhance cellular
responses to viral antigens, autologous dendritic cells were
pulsed with HLA-restricted LMP2 epitope peptides and injected
into inguinal lymph nodes of patients with advanced NPC (Lin et
al., 2002). The treatment elicited epitope-specific CD8+ T cell
responses detectable in the peripheral blood of NPC patients.
Partial clinical response was seen in some selected patients.
The results encourage further development of more effective
vaccine strategies.
Gene therapy
Several gene-based strategies targeting common genetic
abnormalities (e.g., p53 and p16) of NPC have been explored
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(Liu, 2002). Recent exciting development of the “transcriptional
targeting strategy” and utilization of potent membrane-based
apoptotic genes (e.g., FasL) as target have shown promising
results in both in vitro and in vivo studies. To express the target
gene in NPC cells, a recombinant adenovirus containing EBV
oriP promoter at the upstream of the target gene has been gen-
erated. Since oriP sequence is transactivated by EBV latent
protein EBNA1, the vector expresses the target gene only in the
EBV-positive NPC cells (Li et al., 2002; Liu, 2002). The prelimi-
nary findings suggest the high feasibility of using gene therapy
as an alternative treatment for advanced-stage patients.
Future prospects
The high susceptibility of Southern Chinese to develop this dis-
ease is still a puzzle. With recent advances in single nucleotide
polymorphism and haplotype analyses, genome-wide screen-
ing and association studies may help to decipher the inheritable
genetic components for this enigmatic cancer. The cellular
genes involved in DNA damage and its association with EBV
entry or latency should be focused upon and further explored.
Despite the crucial role of EBV in NPC, information about func-
tions of the EBV genes in nasopharyngeal epithelial cells is lim-
ited. Establishment of immortalized normal nasopharyngeal
epithelial cell lines allows us to characterize the EBV gene func-
tions in this specific host environment. It should enhance our
understanding of how the virus adapts itself to the epithelial cell
environment and exerts its effects on malignant transformation.
The cellular genes regulated by EBV are of particular interest,
as they may serve as specific tumor markers and targets for
novel therapy strategies.
Previous molecular studies have focused on the NPC
genome, but few on transcriptomic and proteomic profiles.
Small biopsy material and heavy infiltration of noncancer cells
present major difficulties for these studies. With advances in
microdissection and preamplification technology, comprehen-
sive expression profiling of this lymphoepthelioma is possible.
Early detection is of paramount importance in improving the
prognosis of NPC patients. Selective application of EBV DNA
and epigenetic markers in a serological screening protocol may
prove to be both cost-effective and accurate. The application of
different screening strategies could be tested in high-risk popu-
lations such as Southern Chinese. For NPC treatment, major
challenges remain in improving the survival rate of patients with
advanced and recurrent diseases. In addition to the novel treat-
ments mentioned earlier, clinical application of anti-EGFR anti-
bodies has also been under investigation. The high frequencies
of epigenetic alterations in this cancer suggest the potential
application of novel inhibitors targeting DNA methylation and
histone acetylation. The emerging novel approaches may
brighten up the outcome of NPC patients with poor prognosis.
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